The Relevent disclosure is attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Malar Hospitals has reported its unaudited standalone and consolidated results for the quarter and six months ended September 30, 2025, approved by the Board on November 6, 2025. The company has ceased all business operations following the slump sale of its hospital business to MGM Healthcare in FY24, and management confirms there is no visibility of starting any new business. The Board is evaluating various corporate restructuring options, with results prepared on a going-concern basis supported by cash and bank balances of about Rs 3,247 lakhs. Consolidated operating cash flow turned negative at around Rs (73.85) lakhs for H1 FY26 versus a positive Rs 69.98 lakhs a year ago. The auditor (BSR & Co. LLP) issued an unmodified limited review but highlighted the going-concern matter as an Emphasis of Matter. Additionally, IHH Healthcare's open offer for the company has been re-launched with the price revised downward from Rs 60.10 to Rs 17.60 per share, expected to complete by November 26, 2025.
The company is essentially a shell post the slump sale, with no active business and future dependent on restructuring decisions—this is a significant uncertainty for shareholders. The drastically reduced open offer price (from Rs 60.10 to Rs 17.60) reflects the changed circumstances and may disappoint long-term holders.